SUPPLEMENT PAID DISCOVERY™ · SCIENCE-LED SCOPE LOCK
Supplement Paid Discovery: paid scientific due diligence for one locked supplement brief.
Supplement Paid Discovery starts at EUR 2,500 for one locked professional brief: one SKU, one dosage format, one objective, one target population, one named standard supplement jurisdiction, and no more than five active ingredients. It is a scientific due-diligence gate that validates evidence, regulatory fit, toxicology, dose integrity, and theoretical manufacturability before capital is exposed to bench, pilot, or production spend.
100% PREPAYMENT BEFORE WORK STARTS · EXACTLY 2 CONSOLIDATED REVIEW ROUNDS
This action routes to the written scoped quote intake. It does not promise a free strategy call, direct CEO consultation, or unlimited messaging.
THE PROBLEM WE SOLVE
We evaluate technical, regulatory, and formulation risk before practical spend starts.
Before production-facing work is authorised, the due-diligence scope evaluates recurring technical, regulatory, and formulation failure modes: dose-form mismatch, ingredient interactions, matrix instability, claims-language risk, and jurisdiction-fit conflicts. The objective is to expose decision-critical risk early and route practical, external, and production work into separately scoped paid stages only when the brief is sufficiently defined.
LOCKED BASE UNIT
1 SKU / 1 FORMAT
REVIEW BOUNDARY
2 CONSOLIDATED ROUNDS
PAYMENT GATE
100% PREPAID
PRACTICAL WORK
SEPARATELY SCOPED
The 10 Formulation Failures We Eliminate Before a Single Capsule Is Filled.
- 01.Mineral antagonisms within a single dose
- 02.Missing cofactors and required synergies
- 03.Incorrect molecular form of a vitamin or active ingredient
- 04.Omega-3 oxidation risk and oil matrix stability failures
- 05.Probiotic formulation errors
- 06.Fat-soluble vitamins placed in an incorrect delivery matrix
- 07.Excipient incompatibilities
- 08.Formula matrix and dosage form mismatches
- 09.Botanical-specific formulation errors
- 10.Biochemical blind spots where multiple errors converge simultaneously
None of these are caught by a supplier catalogue, a 5-minute quote, or a standard Excel formula card. We have documented the most common errors in detail — including real-world examples from formulations we declined to produce.
Note: EFSA-approved health claims for individual ingredients do not guarantee the finished product will deliver those claimed effects. The final biochemical matrix — shaped by form, dose, excipient, co-ingredient interactions, and delivery technology — determines actual bioavailability and efficacy. This is precisely where most formulations fail.
READ: COMMON FORMULATION ERRORS →BASE UNIT — PROFESSIONAL SCOPE ONLY
What the EUR 2,500 starting fee actually buys.
The base unit is intentionally narrow: one supplement brief, one formula architecture, up to 20 serious candidates screened, up to five final active ingredients, one named standard supplement jurisdiction, and exactly two consolidated review rounds. It sells disciplined scientific due diligence and documentation only — never physical execution, sourcing, or laboratory work.
STARTING FEE
FROM EUR 2,500
One supplement SKU, one dosage format, one objective, one target population, and one standard supplement jurisdiction.
ACTIVE LIMIT
UP TO 5 ACTIVES
The public base fee covers no more than five active ingredients. Excipients do not count unless they need separate scientific or regulatory justification.
REVIEW BOUNDARY
2 CONSOLIDATED ROUNDS
Exactly two consolidated review rounds from one authorised client representative are included in the professional fee.
PAYMENT GATE
100% PREPAID
Work starts only after cleared payment, completed intake, and signed scope lock. No subjective holdback applies to commencement.
CONTRACTED DELIVERABLES
The professional fee covers the contracted report, formula card, and decision record for the locked supplement brief. The package may include the mechanism map, dose-matched evidence, toxicology screen, claims matrix, screening audit trail, and directional feasibility notes required to support the final recommendation. Completion means delivery of those artifacts and response to two valid consolidated rounds — not a guaranteed regulatory, technical, clinical, or commercial outcome.
WHAT YOU RECEIVE
Decision-Grade Deliverables. Theoretical by Design. Commercially Useful by Intent.
Paid Discovery is 100% intellectual and in-silico work. It gives your team a defensible scientific, regulatory, and commercial foundation before physical development starts, so internal investment decisions, investor diligence, and transfer discussions happen on audited logic rather than optimism.
Mechanism Map & Scientific Thesis
The final report starts with the biochemical mechanism map: the pathways, bottlenecks, and therapeutic thesis the formula must address before any ingredient is approved.
Dose-Matched Evidence Dossier
The evidence layer links active doses to human data, prioritises double-blind randomised controlled trials where available, and records DOI references so the final formula is not built on subclinical fairy-dusting.
Screening Audit Trail
Every accepted and rejected candidate is traceable through the screening sequence, including status-pathway, allergen, claims, safety, and jurisdiction barriers that would otherwise surface too late.
Claims Matrix & Label Guidance
The dossier maps what can and cannot be said in each contracted jurisdiction, including health-claim constraints, warning language, and the public-label implications of the selected actives.
Toxicology & Interaction Screen
The safety review checks tolerable upper limits, NOAEL/UL boundaries, within-formula collisions, contraindications, and drug-pathway risks before practical work is authorised.
Theoretical Galenic Architecture
Olympia maps the theoretical fit of the actives into the chosen dosage form, including flowability, hygroscopicity, density, excipient logic, and clean-label constraints before laboratory work begins.
Formula Card & Directional Feasibility
The deliverables package includes the formula card with precise mass architecture and directional feasibility notes, including preliminary manufacturability assumptions and non-binding COGS direction.
Decision Record & Next-Stage Path
Each brief ends with a governed decision: PROCEED, REDESIGN UNDER NEW SCOPE, PAUSE, or STOP, plus the exact next paid route if practical validation, external verification, pilot, or production planning is justified.
OWNERSHIP & PRODUCTION CREDIT
Portable contracted deliverables after full payment.
After full payment, the contracted Paid Discovery deliverables are portable and may be shared with another manufacturer. Olympia reusable tools, templates, general methods, AI workflows, and background know-how remain outside the deliverable.
EARNED MANUFACTURING CREDIT
Manufacturing Credit is earned, not automatic.
Eligible Paid Discovery professional fees may earn up to 100% Manufacturing Credit under the signed schedule: 50% of the eligible ledger unlocks at the first qualifying commercial production PO for the same SKU and the remaining 50% at the second. Credit is conditional, non-cash and non-refundable, subject to the Finance-approved contribution-margin cap, and never promised as an automatic deduction from the first production order.
GOVERNED ADD-ON LOGIC
Public supplement pricing stays modular, explicit, and finite.
There are no hidden discounts and no silent expansions of the base fee. Named jurisdictions, technology class, active count, and complexity are priced before signature. Ingredients 6–10 add EUR 250 each. Ingredients 11–15 add EUR 400 each after the first tier. Each additional standard supplement jurisdiction adds EUR 500. Complex jurisdictions start at EUR 1,000. More than 15 active ingredients requires manual scientific review.
ACTIVE INGREDIENTS 6–10
+ EUR 250 EACH
Use this tier only after the base five active ingredients are exhausted.
ACTIVE INGREDIENTS 11–15
+ EUR 400 EACH
This second tier applies after the 6–10 ingredient surcharge has already been added.
ABOVE 15 ACTIVES
MANUAL SCIENTIFIC REVIEW
More than 15 active ingredients is outside the public calculator and requires manual scientific review before quoting.
ADDITIONAL STANDARD JURISDICTION
+ EUR 500 EACH
Complex jurisdictions or pathways start at EUR 1,000 and require manual confirmation.
POWDER / SACHET / STICKPACK
+ EUR 750
Applies when the brief needs theoretical taste, dispersion, hygroscopicity, or stickpack architecture before any practical validation work order.
DEMANDING DELIVERY SYSTEMS
FROM EUR 1,500
Liquids, gummies, softgels, emulsions, liposomal systems, and other demanding formats require manual technical review before a final quote is issued.
SEPARATELY QUOTED UNDER THE CANONICAL MODEL
Additional technologies, materially different objectives or populations, new formula architectures, dossier rescue, special status-pathway investigations, and every new SKU are separately quoted. Markets such as EU or GCC must resolve into named countries before quoting. FSMP, medical nutrition, and borderline-regulated products are routine premium Olympia capabilities, but do not enter this public supplement calculator. They proceed through bespoke scientific, regulatory, clinical, technical, and commercial scoping before an individual quotation; no automatic price, scope commitment, feasibility declaration, or Manufacturing Credit is created.
FSMP / MEDICAL NUTRITION
Routine premium capability. Bespoke scope before quotation.
FSMP sits under Regulation (EU) No 609/2013 and Delegated Regulation (EU) 2016/128 rather than the standard supplement pathway. Standard supplement logic is invalid here. The route requires metabolic rationale, borderline-risk analysis, expanded drug-nutrient interaction review, and technical FSMP labeling constraints before quotation.
Olympia Biosciences™ prepares the scientific, regulatory, and legal substantiation package required to defend the route. That does not mean any responsible CDMO can guarantee in advance that a competent authority will ultimately accept the project as FSMP.
Metabolic Rationale
The brief must prove nutritional vulnerability and explain why the pathology requires a specific nutritional intervention rather than a standard wellness formulation.
Borderline Risk Dossier
The route must survive authority scrutiny around category boundaries, intended use, claims language, and the legal distinction from medicinal products.
Advanced Drug-Interaction Review
Nutrient-drug collisions, CYP/P450 pathways, contraindications, and therapy-specific risks are screened at a stricter level than the standard supplement route.
Technical FSMP Labeling
The route requires technical labeling language such as “for the dietary management of …” and physician-supervision wording rather than standard marketing claims.
HOW WE FORMULATE
Eight sequential validation phases before practical spend begins.
Paid Discovery is an in-silico validation protocol, not a prototype sprint. The aim is to expose whether the concept survives scientific, legal, and physical scrutiny before you authorise practical validation, external testing, pilot work, or production commitments.
AI Research Engine Trained on 125 Million Peer-Reviewed Publications
At the candidate screening stage, our proprietary AI model draws on a corpus of over 125 million publications from sources including PubMed — the world's most authoritative biomedical literature database. This is not a keyword search. It is a systematic evidence evaluation that maps dose, form, population, and outcome data for each candidate ingredient. What follows is 13 sequential elimination gates.
Why We Cannot Provide Production Quotes Without This Process.
A spreadsheet accepts any formula. Regulatory authorities approve many flawed formulations. Neither validates scientific integrity. When a product fails to deliver its promised effect — or causes an adverse interaction — the legal and commercial liability falls entirely on the brand owner. Our 13-gate process exists to prevent that outcome. This is why we do not provide production quotes for formulations we have not validated.
RESEARCH SERVICES · METHODOLOGICAL SUPPORT
Where a programme needs a stronger evidence package, Paid Discovery can define the methodological support for literature reviews used in evidence-based scientific assessments: research-question framing, inclusion and exclusion logic, evidence hierarchy, endpoint relevance, contradiction logging and dossier-ready synthesis for the locked brief.
PHASE 1
Mechanism Map
We map the biochemical pathways, signalling routes, and therapeutic bottlenecks that must be influenced before any ingredient is allowed into the candidate pool.
PHASE 2
AI-Assisted Literature Review
Our research layer screens indexed biomedical literature to isolate the dose, form, population, and outcome evidence that matters to the locked brief, then organizes that material into a literature-review method suitable for evidence-based scientific assessment.
PHASE 3
Sequential Elimination Funnel
Candidates are cut through sequential scientific, legal, allergen, claims, and jurisdiction filters so weak, risky, or non-portable options are removed early.
PHASE 4
Claims Engineering
We map what can be claimed in the contracted jurisdictions and separate commercially useful language from wording that would expose the brand to enforcement risk.
PHASE 5
Dose-Matched Evidence
The selected actives are matched against clinically relevant doses and forms so the final architecture does not rely on decorative inclusion levels.
PHASE 6
Toxicology & Interaction Review
We screen upper limits, contraindications, nutrient-nutrient conflicts, and drug-pathway interactions before the brief advances toward physical execution.
PHASE 7
Theoretical Galenic Design
The brief is tested in theory against form-factor physics, excipient logic, density, flowability, hygroscopicity, and clean-label constraints.
PHASE 8
Directional Feasibility
We close with decision-grade commercial direction: manufacturability assumptions, directional COGS logic, and the exact point where separately paid practical work must begin.
A 4:1 extract does not produce the same clinical effect as a standardised extract. A standardised extract produced with a different extraction technology creates a different biochemical matrix from the one described in the underlying literature, even when the marker percentage looks similar. Paid Discovery exists to stop those false equivalences before they turn into expensive physical work.
NOT INCLUDED IN THE PROFESSIONAL FEE
Physical execution, third-party verification, and production economics stay outside the base scope.
- Laboratory work, bench trials, prototypes, and client samples
- Flavour work, sensory work, materials, sourcing, and supplier qualification
- Validated COGS, supplier pricing, stability, analytics, microbiology, and heavy-metal testing
- Filings, registrations, notifications, pilot, scale-up, batch records, and finished-product CoA
- Packaging procurement, shipping, logistics, and commercial production
NEXT SEPARATELY PAID STAGES
Practical Validation Work Order
Used for physical formulation work such as prototypes, samples, flavour/sensory iterations, materials, sourcing, supplier qualification, and practical trials.
External Verification Work Order
Used for accredited analytical, microbiological, contaminant, identity, potency, and other external laboratory verification.
Pilot & Industrialisation
Used for pilot batches, process confirmation, scale-up evidence, line parameters, and industrial execution planning.
Commercial Production
Quoted separately under production economics, quality scope, and accepted commercial terms after the governed pre-production stages are complete.
What determines supplement manufacturing cost?
A reliable manufacturing cost cannot be established from a product name alone. It depends on the formula and dosage system, product format, packaging requirements, batch scale, target-market and labelling needs, verification requirements and supply constraints. Olympia first defines the relevant technical and commercial inputs; a production quotation follows only when the scope is sufficiently specified.
Paid Discovery is the paid, bounded decision step for a supplement project. Physical validation, external testing, packaging procurement, supplier-validated COGS, pilot work and commercial production are separately scoped. FSMP and medical-nutrition programmes follow bespoke scoping and individual pricing.
PORTABILITY · RIGHTS · BESPOKE SCOPING
Portable deliverables, contained rights, and bespoke scope boundaries.
The paid report is portable and may be shared with another manufacturer. Olympia reusable tools, templates, general methods, AI workflows, and background know-how are not part of the deliverable. FSMP, medical nutrition, and borderline-regulated products follow Olympia’s bespoke scoping and quotation path outside the public supplement calculator. No automatic price, SoW, feasibility declaration, or Manufacturing Credit is created before confirmed scope.
Paid Discovery can conclude with PROCEED, REDESIGN UNDER NEW SCOPE, PAUSE, or STOP. The fee buys disciplined analysis and clear deliverables for the locked supplement brief — not a guaranteed external, regulatory, manufacturing, or commercial result.
Use the intake to lock the supplement brief, declare jurisdictions and actives, and receive the governed quote path. No free strategy call, no extended-scope additions, and no unqualified executive access are bundled into the base fee.
RELATED INTELLIGENCE